FDA Inspection 1304580 — Wyeth BioPharma Division Of Wyeth Pharmaceuticals LLC
The FDA completed an inspection of Wyeth BioPharma Division Of Wyeth Pharmaceuticals LLC on Feb 11, 2026 in Andover, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 11, 2026
- Fiscal Year
- 2026
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Andover, MA (United States)